Question 13779 — pharmacy and medications

Summary

Ms. Huguette Tiegna draws the attention of the Minister of Solidarity and Health to new treatments that could improve and prolong the lives of patients with multiple myeloma (AF3M). Multiple myeloma is a rare disease little known to the general public which affects nearly 5,000 new people each year. It is estimated that 30,000 people are affected by it today in France. Delivery by the European Medicines Agency marketing authorization in Europe for 5 new drugs since the end of 2015 (panobinostat, ixazomib, carfilzomib, daratumumab and elotuzumab) has given rise to real hope and constituted a crucial step for health personnel and patients for whom access to these new drugs constitutes not only an emergency but above all a question of survival. For example, Carfilzomib meets all the conditions for being included on the so-called “extra” list allowing reimbursement to hospitals by health insurance. She would like to know its position on the subject of making these innovative medicines available.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.